Saturday, April 13, 2013 6:02:32 PM
Thanks for the links Bio - forwarded them on to my internist, who specializes in patients with Lyme disease + coinfections and heavy metal poisoning - he's not a PCP, not even close - most of his patients have occasional or permanent cognitive function impairments. I emailed him that new magnesium supplement info yesterday along with a PR from AMRN about inflammatory marker reductions and off label usage for that purpose. He's very big into trying off label or alternative approaches to treating his patients, as Western medicine is seriously lacking in helping folks with the conditions I mentioned above. His reply this morning:
thanks for the info
cool stuff
i had not heard of Vasecpa need to look at dosage and quality of it vs. Lovaza which is another longer standing prescription fish oil
I wouldn't worry about him not being aware of V yet, he doesn't have the kind of practice that an AMRN rep would visit, and he's so frigging busy (3-4 month waits to get an appt. are routine) he has little spare time to keep up with general medicine news - I'm his unpaid "research assistant", keep him up to date on new drug/supplement developments with the potential to treat me and others with similar health problems via email.
I've actually never even seen a drug rep in their offices in the 7 yrs he's been treating me - he's very big into using natural dietary supplements/vitamins/minerals/herbs as substitutes for drugs whenever feasible. Last year he held a series of lectures open to the public, the topic of one of them was how chronic inflammation is the root cause of most evils, so after he does his DD I'm sure he start experimenting with V, perhaps on me
- I see him 1st week of May.
thanks for the info
cool stuff
i had not heard of Vasecpa need to look at dosage and quality of it vs. Lovaza which is another longer standing prescription fish oil
I wouldn't worry about him not being aware of V yet, he doesn't have the kind of practice that an AMRN rep would visit, and he's so frigging busy (3-4 month waits to get an appt. are routine) he has little spare time to keep up with general medicine news - I'm his unpaid "research assistant", keep him up to date on new drug/supplement developments with the potential to treat me and others with similar health problems via email.
I've actually never even seen a drug rep in their offices in the 7 yrs he's been treating me - he's very big into using natural dietary supplements/vitamins/minerals/herbs as substitutes for drugs whenever feasible. Last year he held a series of lectures open to the public, the topic of one of them was how chronic inflammation is the root cause of most evils, so after he does his DD I'm sure he start experimenting with V, perhaps on me
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
